Immunotherapy Plus Chemo Benefits Patients with NSCLC 🔗 Access full article via CureTodayPatients with a history of proton pump inhibitor use and who have NSCLC with a PD-L1 tumor proportion score of 50% or more benefit from immune checkpoint inhibitor plus chemotherapy as treatment. Share:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
